Greg Ver­dine will have many new C-suite friends at fun­gus biotech LifeM­ine af­ter GSK-fu­eled $175M round

A year af­ter se­cur­ing funds from Rick Klaus­ner and adding No­bel lau­re­ate William Kaelin to the board, fun­gus-fo­cused LifeM­ine Ther­a­peu­tics is ready to re­veal the Big Phar­ma part­ner it’s spent more than two years court­ing, with Hal Bar­ron in­volved, and the dry pow­der it’s been reel­ing in since Oc­to­ber.

The biotech is head­ed in­to its next chap­ter with Glax­o­SmithK­line, and an­oth­er “half a dozen” phar­mas are in the hop­per for po­ten­tial part­ner­ships, co-founder and CEO Greg Ver­dine told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER